Todd M Pitts Selected Research

Todd M Pitts Research Topics

Disease

53	Neoplasms (Cancer) 04/2024 - 09/2009
28	Colorectal Neoplasms (Colorectal Cancer) 03/2024 - 02/2009
10	Triple Negative Breast Neoplasms 01/2024 - 01/2013
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2024 - 04/2016
4	Melanoma (Melanoma, Malignant) 01/2021 - 02/2015
3	Adenocarcinoma 04/2024 - 01/2018
2	Inflammation (Inflammations) 01/2023 - 04/2003
2	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 09/2009
2	Aneuploidy (Aneuploid) 11/2019 - 10/2018
2	Disease Progression 01/2018 - 01/2016
2	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2016
2	Colonic Neoplasms (Colon Cancer) 01/2013 - 02/2009
2	Endotoxemia 04/2003 - 09/2002
2	Acute Lung Injury 04/2003 - 09/2002
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2021
1	Adrenocortical Carcinoma 01/2020
1	Fibrosis (Cirrhosis) 01/2019
1	Polyploidy 01/2018
1	Exanthema (Rash) 01/2018
1	Hypertension (High Blood Pressure) 01/2018
1	Neutropenia 04/2016

Drug/Important Bio-Agent (IBA)

16	Phosphotransferases (Kinase)IBA 10/2022 - 09/2002
9	Irinotecan (Camptosar)FDA LinkGeneric 10/2022 - 11/2010
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2012
8	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 12/2010
6	ENMD 2076IBA 10/2018 - 06/2010
5	Aurora Kinase AIBA 04/2024 - 06/2010
5	AZD 6244IBA 01/2018 - 12/2010
4	MLN 8237IBA 04/2024 - 05/2015
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
4	LigandsIBA 01/2022 - 09/2009
4	Proteins (Proteins, Gene)FDA Link 01/2018 - 11/2013
3	Histone Deacetylase InhibitorsIBA 01/2024 - 02/2009
3	Gemcitabine FDA Link 01/2024 - 04/2016
3	Tyrosine Kinase InhibitorsIBA 01/2022 - 11/2013
3	cabozantinibIBA 01/2022 - 04/2015
3	Capecitabine (Xeloda)FDA Link 01/2021 - 04/2016
3	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 12/2018 - 11/2010
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2016 - 09/2009
2	sapanisertibIBA 04/2024 - 01/2020
2	Mechanistic Target of Rapamycin Complex 1IBA 04/2024 - 01/2020
2	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2018
2	CytokinesIBA 01/2023 - 01/2021
2	Fluorouracil (Carac)FDA LinkGeneric 10/2022 - 11/2010
2	Granzymes (Granzyme)IBA 01/2022 - 01/2020
2	Protein Isoforms (Isoforms)IBA 01/2022 - 01/2018
2	Histones (Histone)IBA 01/2022 - 10/2019
2	adavosertibIBA 01/2021 - 03/2020
2	CateninsIBA 11/2020 - 11/2019
2	RX-5902IBA 11/2020 - 11/2019
2	Insulin ReceptorIBA 12/2018 - 11/2013
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2018 - 11/2010
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2018 - 08/2013
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 04/2016 - 09/2009
2	TAK 733IBA 10/2015 - 02/2015
2	Aurora KinasesIBA 01/2013 - 02/2011
2	PF 3758309IBA 01/2013 - 01/2013
2	Vorinostat FDA Link 02/2012 - 02/2009
2	IGF Type 1 Receptor (IGF 1 Receptor)IBA 11/2010 - 06/2010
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2024
1	ETC-159IBA 01/2024
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2024
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2024
1	Dinoprostone (PGE2)FDA Link 01/2023
1	Interleukin-2 (IL2)IBA 01/2023
1	Topoisomerase I InhibitorsIBA 10/2022
1	AZD0156IBA 10/2022
1	HLA-DR Antigens (HLA-DR)IBA 01/2022
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2022
1	NivolumabIBA 01/2022
1	Hormones (Hormone)IBA 03/2020
1	pembrolizumabIBA 01/2020
1	Insulin (Novolin)FDA Link 12/2018
1	SBI-0206965IBA 10/2018
1	tyrosine receptor (receptor, tyrosine)IBA 10/2018
1	regorafenibIBA 10/2018
1	Chloroquine (Aralen)FDA LinkGeneric 10/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Enterotoxin ReceptorsIBA 01/2018
1	CreatinineIBA 01/2018
1	entrectinibIBA 01/2018
1	indusatumabIBA 01/2018
1	4- ((9- cyclopentyl- 7,7- difluoro- 5- methyl- 6- oxo- 6,7,8,9- tetrahydro- 5H- pyrimido(4,5- b)(1,4)diazepin- 2- yl)amino)- 2- fluoro- 5- methoxy- N- (1- methylpiperidin- 4- yl)benzamideIBA 01/2018
1	AldosteroneIBA 01/2018
1	Immunoconjugates (Immunoconjugate)IBA 01/2018
1	Adenosine Triphosphate (ATP)IBA 01/2018
1	Dasatinib (BMS 354825)FDA Link 01/2017
1	pevonedistatIBA 01/2017
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2017
1	TankyrasesIBA 05/2016
1	Epidermal Growth Factor (EGF)IBA 04/2016
1	vandetanib (ZD6474)IBA 04/2016
1	Indicators and Reagents (Reagents)IBA 01/2016

Therapy/Procedure

18	Therapeutics 04/2024 - 06/2010
4	Immunotherapy 12/2022 - 01/2016
2	Drug Therapy (Chemotherapy) 01/2021 - 11/2010
2	Aftercare (After-Treatment) 01/2017 - 06/2012
1	Precision Medicine 12/2022
1	Subcutaneous Injections 01/2016